Makes sense, and a reasonable concern in my mind. I do think that for combo therapy, the fact that it is an unmet medical need will largely help the drug to sell itself. I would think that in a given medical field, any new therapy approved for an unmet medical need will be well known to physicians without the need for a truly effective sales force. Maybe I'm being naive? Mono may not sell itself, but that's a long ways off at this point, and the drug should be well into market by then so hopefully it will have made a name for itself at that point. Honestly, cancer will likely hit the market before mono.

Which is why I still give it some likelihood that Vyera never sells a dose and we all consider that a good thing. This deal bought the breathing room and leverage, but the next 3-4 cancer patients in the naïve protocol could really bring it all home. Neither BP nor the FDA seem to play around where oncology is involved. Just need to get those patients dosed ASAP, and maybe the company can get something shaking prior to needing a new round of funding.